Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9720MR)

This product GTTS-WQ9720MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9720MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10163MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ7728MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ6051MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ959MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ2726MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ335MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ23MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ10619MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW